[ASH巅峰访谈]EHA主席Tony Green教授：大会精彩亮点回顾

EHA主席、英国剑桥大学临床医学院  Tony Green教授

　　请您和我们分享一下今年ASH-ASH联合论坛的亮点内容?此外本届大会您关注哪些研究?

　　Green主席:当然。今年我参加的ASH-EHA论坛会议就非常的精彩，其中一项议题：多潜能干细胞及其临床应用让我非常兴奋。其中两位讲者，来自波士顿的George Daley教授和德国的Oliver Brüstle教授的演讲内容十分精彩。George Daley主要演讲内容分为多潜能干细胞的血液分化；Oliver Brüstle则更多谈到多潜能干细胞向神经细胞的分化方向。

　　关于其他领域的研究热点，大会发言中我看到了6项精彩的摘要报道均有非常令人兴奋的研究结果。关于临床研究结果方面，一些非常有趣的研究结果也被报道，如抗病毒治疗的血友病患者可能不再需要相关凝血因子的补充治疗，所以除了证明关于血友病的基因治疗正在稳步前进之外，这对于血友病患者来说无疑是极好的福音。此外，一项关于镰状细胞贫血的临床研究再次被报道，该研究指出2P选择素抗体极有可能组织血小板与红细胞的粘附，这一特性有可能对于镰状细胞贫血的患者有临床意义。还有一项研究提出，线粒体有可能从造血干细胞传递至基质细胞，这有可能是机体逃避氧化应激的一种方式。换句话说，尽管存在别的信号通路的激活，干细胞本身有可能可以控制氧化应激反应。同时，这种线粒体的传递似乎有两种方式。总之，上述研究结果都非常有意义而且令人兴奋，而这也只是本届ASH盛会中众多亮点的一个。

　　Dr. Green: Certainly. As always， there are many highlights at ASH， but if I were to select just a few that have been particularly exciting， there was a very good session—this was a join ASH-EHA session—on pluripotent stem cells and whether they will be of clinical use. And they had two fantastic speakers: George Daley， from Boston， and Oliver Brüstle， from Germany. So， George Daley talked mainly about the blood side of pluripotent stem cells and how they can be used to generate blood cells， and Oliver Brüstle talked more about the neurological side.And both gave fantastic talks. And then， other areas or highlights， I think， the plenary session had the six best abstracts presented and within there， they had some really very exciting results. On a clinical level，they had the results of a new trial of factor IX hemophilia using anti-viruses and they really do look now is if they are， essentially， able to stop having to use factor concentrates. So， this is a remarkable result for patients with hemophilia. So， that’s gene therapy for hemophilia really succeeding.

　　There was， and again， an interesting clinical trial in sickle cell disease， suggesting that antibodies 2p selectin—which， presumably， are blocking adhesion of platelets and red cells—have clinical effectiveness in patients with sickle cell disease. So， that’s very exciting. And then， there’s some fantastic basic science as well. Solapado has a story that mitochondria can be passed down from blood stem cells to stromal cells and this may be a way of getting rid of reactive oxygen species—so， a way the stem cells could control ROS. But there may also be other signaling “cascades，” as it were， that are triggered. And it looks as if the mitochondrial transfer might be two-way. So， again， that’s very surprising， very interesting. So， just a few of the exciting things that have happened at ASH.

　　作为EHA主席，请您介绍一下明年EHA年会的筹备情况？

　　Green主席:2017年6月，欧洲血液学会（EHA）年会将在西班牙马德里举办。那是一座风景秀丽的城市，我们将非常期待。目前，有关大会的筹备目前仍在进行当中，相信一定会有很多精彩的内容不容错过。与往届相比，下届EHA年会我们将更加关注支持年轻科学家以及临床医生参与的项目。事实上，EHA年会上我们设置了为期一天的可供青年研究者们交流、展示他们成果的平台。此外，我们还会如以往一样举办非常精彩的继续教育项目，同时将会有一大批全球内享有盛誉的讲者在会议上发表他们的研究成果。我相信，下届EHA年会也会是值得我们期待的一场盛会。

　　Dr. Green: Next year at EHA. So next year it will be， as always， in June. Next year it’s going to be in Madrid， in Spain. And so we are looking forward to that. It’s going to be a beautiful venue. And the program is not finalized yet， but it will certainly contain some new things， particularly trying to support the younger trainees—both the scientists and the clinicians—and so there’s going to be a particular emphasis on them. And there’s actually going to be a whole day meeting immediately before EHA for youngsters to present their research. And then there will be a usual mixture of a very active educational program—internationally renowned invited speakers presenting their work in scientific sessions—and the usual invited abstracts， posters， oral sessions， etcetera. So， it should be another， very exciting meeting.

　　明年中国临床肿瘤学会（CSCO）将会迎来20周年盛会。我们可以邀请您给中国的临床肿瘤学家、医生以及研究者一些寄语吗？

　　Green 主席:万分荣幸！在此我谨代表EHA，庆贺中国临床肿瘤学会成立20周年！非常期待与中国肿瘤学研究团体以及中国血液学领域的专家们加强交流学习。作为一个血液学研究的组织，EHA非常期待加强欧洲血液学家与肿瘤医生与中国同道的联系，这也是我个人非常期待的！

　　Dr. Green: Thank you. So I wish CSCO a very happy birthday next year. Happy twelfth birthday. And， I think， on behalf of EHA， I think I can very strongly say we are looking forward to strengthening our interactions with the oncology community in China， like CSCO， and also with the hematology community in China. So， as an organization， EHA is very keen to further strength the links between the European hematologists and cancer doctors and those in China. So I’m looking forward to that.